Literature DB >> 29976999

Genotype-phenotype correlation in Becker muscular dystrophy in Chinese patients.

Ruiyi Yuan1,2, Junfei Yi1, Zhiying Xie1, Yimeng Zheng1, Miao Han3, Yue Hou4, Zhaoxia Wang1, Yun Yuan5.   

Abstract

Large deletions and duplications are the most frequent causative mutations in Becker muscular dystrophy (BMD), but genetic profile varied greatly among reports. We performed a comprehensive molecular investigation in 95 Chinese BMD patients. All patients were divided into three subtypes: normal muscle strength (type 1) in 18 cases, quadriceps myopathy (type 2) in 20 cases, and limb-girdle weakness (type 3) in 57 cases. Nineteen cases (20.0%) had small mutations and 76 cases (80.0%) had major rearrangements, including 67 cases (70.5%) of exonic deletions and 9 cases (9.5%) of exonic duplications. We identified 50 cases (65.8%) of in-frame mutations, and 26 cases (34.2%) of frame-shift mutations. The frequency of deletion in exons 13-19 was 30.6% in type 1 patients, 9.7% in type 2 patients, and 10.4% in type 3 patients. The frequency of deletion in exons 45-55 was 28.6% in type 1 patients, 40.8% in type 2, and 50.0% in type 3 patients. All major rearrangements of DMD gene in type 1 patients were also observed in type 3 patients. Our study suggested that frame-shift mutation was not rare in Chinese BMD patients. Although no difference was observed on the forms of DMD gene mutations among the three types of patients, the mutation in proximal region of DMD gene has higher frequency for patients without weakness. Effect of exon skipping for DMD depends on the size and location of the mutation. Additional studies are required to determine whether exon-skipping strategies in proximal region of DMD gene could yield more functional dystrophin.

Entities:  

Mesh:

Year:  2018        PMID: 29976999     DOI: 10.1038/s10038-018-0480-5

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  35 in total

1.  Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families.

Authors:  M A Melis; M Cau; F Muntoni; A Mateddu; R Galanello; L Boccone; F Deidda; D Loi; A Cao
Journal:  Eur J Paediatr Neurol       Date:  1998       Impact factor: 3.140

2.  Becker muscular dystrophy with marked divergence between clinical and molecular genetic findings: case series.

Authors:  G P Ramelli; F Joncourt; J Luetschg; J Weis; M Tolnay; J M Burgunder
Journal:  Swiss Med Wkly       Date:  2006-03-18       Impact factor: 2.193

3.  Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy.

Authors:  Akinori Nakamura; Naoko Shiba; Daigo Miyazaki; Hitomi Nishizawa; Yuji Inaba; Noboru Fueki; Rika Maruyama; Yusuke Echigoya; Toshifumi Yokota
Journal:  J Hum Genet       Date:  2016-12-15       Impact factor: 3.172

4.  Single amino acid loss in the dystrophin protein associated with a mild clinical phenotype.

Authors:  Roser Pons; Kyriaki Kekou; Artemis Gkika; George Papadimas; Nikolaos Vogiatzakis; Maria Svingou; Constantinos Papadopooulos; Ioanis Nikas; Argirios Dinopoulos; Sotiris Youroukos; Emmanouel Kanavakis
Journal:  Muscle Nerve       Date:  2016-10-28       Impact factor: 3.217

5.  Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45.

Authors:  Andrew R Findlay; Nicolas Wein; Yuuki Kaminoh; Laura E Taylor; Diane M Dunn; Jerry R Mendell; Wendy M King; Alan Pestronk; Julaine M Florence; Katherine D Mathews; Richard S Finkel; Kathryn J Swoboda; Michael T Howard; John W Day; Craig McDonald; Aurélie Nicolas; Elisabeth Le Rumeur; Robert B Weiss; Kevin M Flanigan
Journal:  Ann Neurol       Date:  2015-03-02       Impact factor: 10.422

6.  Whole dystrophin gene analysis by next-generation sequencing: a comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy.

Authors:  Yan Wang; Yao Yang; Jing Liu; Xiao-Chun Chen; Xin Liu; Chun-Zhi Wang; Xi-Yu He
Journal:  Mol Genet Genomics       Date:  2014-04-27       Impact factor: 3.291

7.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities.

Authors:  K M Bushby; D Gardner-Medwin; L V Nicholson; M A Johnson; I D Haggerty; N J Cleghorn; J B Harris; S S Bhattacharya
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

8.  Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up.

Authors:  Francesca Magri; Alessandra Govoni; Maria Grazia D'Angelo; Roberto Del Bo; Serena Ghezzi; Gandossini Sandra; Anna Carla Turconi; Monica Sciacco; Patrizia Ciscato; Andreina Bordoni; Silvana Tedeschi; Francesco Fortunato; Valeria Lucchini; Sara Bonato; Costanza Lamperti; Domenico Coviello; Yvan Torrente; Stefania Corti; Maurizio Moggio; Nereo Bresolin; Giacomo Pietro Comi
Journal:  J Neurol       Date:  2011-03-12       Impact factor: 4.849

9.  Early-progressive dilated cardiomyopathy in a family with Becker muscular dystrophy related to a novel frameshift mutation in the dystrophin gene exon 27.

Authors:  Takeshi Tsuda; Kristi Fitzgerald; Mena Scavena; Samuel Gidding; Mary O Cox; Harold Marks; Kevin M Flanigan; Steven A Moore
Journal:  J Hum Genet       Date:  2014-12-24       Impact factor: 3.172

Review 10.  Skipping Multiple Exons to Treat DMD-Promises and Challenges.

Authors:  Tejal Aslesh; Rika Maruyama; Toshifumi Yokota
Journal:  Biomedicines       Date:  2018-01-02
View more
  1 in total

Review 1.  Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine.

Authors:  Nalinda B Wasala; Shi-Jie Chen; Dongsheng Duan
Journal:  Expert Opin Drug Discov       Date:  2020-01-30       Impact factor: 6.098

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.